Tagged with Holland

Pharma The following chart shows the massive potential in the Dutch pharmaceuticals and healthcare markets; a population of almost 17 million with high per capita GDP where a large percentage of the population have long-term health conditions. Click here to read more articles and interviews from the Netherlands, and to download…

Pharma Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015 Global Innovation Index. For the healthcare sector, the country’s innovation is notably propelled by a myriad of local success-stories, and…

Pharma In keeping with its reputation as a forerunner, the Dutch healthcare eco-system is currently reinventing itself to ensure it remains ahead of the game in terms of both innovation and excellence. Market and patient access, transparency, cost-effectiveness and process innovation all feature prominently as industry and government alike band together…

Pharma The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an overall approach to treating patients. Aging population, chronic disease, and innovative pharmaceutical treatments’ role in extending patients’ life expectancies have…

Pharma Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager for Benelux shares the plans of the company for the Netherlands and Benelux, how Sobi is transforming its product portfolio,…

Pharma In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of Philips Research since 2007, a centenarian institution that stands as one of the largest private research organizations in the world.…

Pharma Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his perspective on how patient and hospital management will evolve in the future. In April 2014 Zimmer announced the acquisition of…

Pharma Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in the Netherlands and your global ambitions, a truly ambitious culture emanates from TEVA’s achievements. Where does this drive come from?…

Pharma Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses the need for more transparency in the pharmaceutical industry and highlights the need for all stakeholders in the industry to…

Pharma DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB Schenker announced the company’s Vision 2020. Can you please elaborate on this vision? BC: This strategy is about being an eco-pioneer,…

Pharma Roeland Van Dam, CEO of Bilthoven Biologicals, a historical Dutch company which remains at the forefront of vaccine production, explains how being integrated into the Serum Institute of India has helped the company to become profitable and consider ambitious new objectives. Bilthoven Biologicals has a very unique history, having started…

Pharma Han Brouwer, General Manager for Actelion in the Netherlands, explains how Opsumit’s successful market launch has strengthened Actelion’s leadership position in the pulmonary arterial hypertension (PAH) field. He calls for a more comprehensive approach to the disease life cycle and for more transparency during market access procedures while the Dutch…